Are taxanes the future for head and neck cancer? Pragmatism in the immunotherapy era

Lancet Oncol. 2021 Apr;22(4):413-415. doi: 10.1016/S1470-2045(21)00121-2. Epub 2021 Mar 5.

Authors

Michael Hwang¹, Tanguy Y Seiwert²

Affiliations

¹ Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.
² Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA; The Bloomberg Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA. Electronic address: tseiwert@jhmi.edu.

PMID: 33684371
DOI: 10.1016/S1470-2045(21)00121-2

No abstract available

Publication types

Comment

MeSH terms

Cetuximab
Cisplatin
Docetaxel
Fluorouracil
Head and Neck Neoplasms* / drug therapy
Humans
Immunotherapy / adverse effects
Platinum
Taxoids*

Substances

Taxoids
Docetaxel
Platinum
Cetuximab
Cisplatin
Fluorouracil

Associated data

ClinicalTrials.gov/NCT02551159
ClinicalTrials.gov/NCT02741570